T
Thomas F. Lüscher
Researcher at University of Zurich
Publications - 1613
Citations - 88517
Thomas F. Lüscher is an academic researcher from University of Zurich. The author has contributed to research in topics: Endothelium & Myocardial infarction. The author has an hindex of 134, co-authored 1560 publications receiving 79034 citations. Previous affiliations of Thomas F. Lüscher include University of Texas Southwestern Medical Center & Durham University.
Papers
More filters
Journal ArticleDOI
Endothelial dysfunction in aorta of the spontaneously hypertensive, stroke-prone rat: effects of therapy with verapamil and trandolapril alone and in combination.
TL;DR: The effects of chronic therapy with the angiotensin-converting enzyme (ACE) inhibitor trandolapril and/or Ca2+ antagonist verapamil on endothelial and vascular smooth muscle (VSM) function were studied in spontaneously hypertensive, stroke-prone rats (SHRSP).
Journal ArticleDOI
Exercise: friend or foe?
TL;DR: A sustained increase in physical activity is likely to require more than individual advice, and needs to include urban planning and possibly even legislation, to encourage exercise in the population.
Journal ArticleDOI
Rationale and design of dal-VESSEL: a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-mediated vasodilatation
John J.P. Kastelein,Raphaël Duivenvoorden,John E. Deanfield,Eric de Groot,J. Wouter Jukema,Juan Carlos Kaski,Thomas Münzel,Stefano Taddei,Valerie Lehnert,Tracy Burgess,David Kallend,Thomas F. Lüscher +11 more
TL;DR: The study assesses efficacy and safety of dalcetrapib on endothelial function, blood pressure, lipids, and clinical outcomes in CHD patients with below average HDL-C and will provide vital information regarding its potential role in the preventative treatment of CHD risk.
Journal ArticleDOI
Cyclophilin A differentially activates monocytes and endothelial cells: role of purity, activity, and endotoxin contamination in commercial preparations.
Sravan Payeli,Cordelia Schiene-Fischer,Jan Steffel,Giovanni G. Camici,Izabela Rozenberg,Thomas F. Lüscher,Felix C. Tanner +6 more
TL;DR: Pure, active, and uncontaminated CyPA does not induce endothelial TF or VCAM-1 expression; instead, it acts as a potent monocyte chemoattractant and induces monocyte Il-6 release, implying a role for extracellular CyPA in the pathogenesis of atherosclerosis via activation of monocytes rather than endothelial cells.
Journal ArticleDOI
Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland
Roland Klingenberg,Dik Heg,Lorenz Räber,David Carballo,David Nanchen,Baris Gencer,Reto Auer,Milosz Jaguszewski,Barbara E. Stähli,Philipp Jakob,Christian Templin,Giulio G. Stefanini,Bernhard Meier,Pierre Vogt,Marco Roffi,Willibald Maier,Ulf Landmesser,Nicolas Rodondi,François Mach,Stephan Windecker,Peter Jüni,Thomas F. Lüscher,Christian M. Matter +22 more
TL;DR: Patients treated with prasugrel according to current guidelines (ie, in patients without cerebrovascular disease, old age or underweight) had a similar safety profile compared with patients treated with clopidogrel.